---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335368"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-08-05T20:55:14+00:00"
generated_at: "2026-08-05T20:56:15.683115+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial

## Summary
- Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.
- First participant dosed in QUELL-CV Phase 2 trial of BGE-102 (NLRP3 inhibitor); topline data expected H2 2026.
- Cash, cash equivalents, and marketable securities $381.3M as of June 30, 2026; sufficient through 2029.
- QUELL-DME Phase 1b/2a trial in diabetic macular edema planned to start mid-2026, data mid-2027.
- Collaboration revenue flat at $2.4M; APJ agonist IND planned by year-end 2026.

## SEC filing metadata
- accession: 0001193125-26-335368
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-08-05T20:55:14+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/0001193125-26-335368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526335368/bioa-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335368
- JSON: https://secwatch.observer/filing/0001193125-26-335368.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.